TRAW
Traws Pharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.55
+1.49%0
Insider buys (3m)
0
Insider sells (3m)
$0.00
Net value (3m)
-59.9%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Jul 16, 2026 | Pauza Charles David · officer: Chief Science Officer Virology | A-Award | 97,000 | $0.68 |
| Jul 15, 2026 | Savchuk Nikolay · director, officer: Chief Operating Officer | A-Award | 93,000 | $0.68 |
| Jul 15, 2026 | CAUTREELS WERNER · director | A-Award | 14,150 | $0.68 |
| Jul 14, 2026 | STOVER JACK E · director | A-Award | 14,150 | $0.68 |
| Jul 14, 2026 | Leaman John Harold · director | A-Award | 14,150 | $0.68 |
| Jul 14, 2026 | Clarke Trafford · director | A-Award | 14,150 | $0.68 |
| Jul 14, 2026 | Shoemaker Mary Teresa · director | A-Award | 14,150 | $0.68 |
| Jul 14, 2026 | Parker Charles Nolan · officer: Chief Financial Officer | A-Award | 90,000 | $0.68 |
| Jul 14, 2026 | Redfield Robert · officer: Chief Medical Officer | A-Award | 84,000 | $0.68 |
| Jul 14, 2026 | Dukes Iain D. · director, officer: Chief Executive Officer | A-Award | 274,000 | $0.68 |
| Apr 28, 2026 | ORBIMED ADVISORS LLC · 10 percent owner | Purchase | 597,729 | $1.67 |
| Apr 28, 2026 | ORBIMED ADVISORS LLC · 10 percent owner | Purchase | 1,793,187 | $1.67 |
| Apr 8, 2026 | Parker Charles Nolan · officer: Chief Financial Officer | A-Award | 104,544 | $1.60 |
| Apr 8, 2026 | Parker Charles Nolan · officer: Chief Financial Officer | A-Award | 61,571 | $2.33 |
| Apr 8, 2026 | Parker Charles Nolan · officer: Chief Financial Officer | A-Award | 32,406 | $3.01 |
| Apr 8, 2026 | Parker Charles Nolan · officer: Chief Financial Officer | A-Award | 15,393 | $0.00 |
| Mar 10, 2026 | CAUTREELS WERNER · director | A-Award | 31,258 | $1.60 |
| Mar 10, 2026 | Clarke Trafford · director | A-Award | 33,435 | $1.60 |
| Mar 10, 2026 | Redfield Robert · officer: Chief Medical Officer | A-Award | 108,854 | $1.60 |
| Mar 10, 2026 | Shoemaker Mary Teresa · director | A-Award | 33,435 | $1.60 |
| Mar 10, 2026 | STOVER JACK E · director | A-Award | 33,435 | $1.60 |
| Mar 10, 2026 | Savchuk Nikolay · director, officer: Chief Operating Officer | A-Award | 96,899 | $1.60 |
| Mar 10, 2026 | Pauza Charles David · officer: Chief Science Officer Virology | A-Award | 118,367 | $1.60 |
| Mar 10, 2026 | Dukes Iain D. · director, officer: Chief Executive Officer | A-Award | 231,336 | $1.60 |
| Mar 10, 2026 | Leaman John Harold · director | A-Award | 33,435 | $1.60 |
| Dec 16, 2025 | Leaman John Harold · director | A-Award | 16,234 | $2.33 |
| Dec 16, 2025 | Leaman John Harold · director | A-Award | 4,058 | $0.00 |
| Dec 16, 2025 | Clarke Trafford · director | A-Award | 24,629 | $2.33 |
| Dec 16, 2025 | Clarke Trafford · director | A-Award | 6,157 | $0.00 |
| Dec 16, 2025 | CAUTREELS WERNER · director | A-Award | 4,874 | $0.00 |
Institutional positioning
13F filings over the trailing two quarters
New 14Increased 2Reduced 4Sold out 29
| Filer | Action | Shares | Filed |
|---|---|---|---|
| ADAGE CAPITAL PARTNERS GP, L.L.C. | Unchanged | 730,000 | May 15, 2026 |
| IKARIAN CAPITAL, LLC | Unchanged | 678,142 | May 15, 2026 |
| ORBIMED ADVISORS LLC | Unchanged | 605,531 | May 15, 2026 |
| Squadron Capital Management LLC | Reduced | 511,714 | May 15, 2026 |
| DAUNTLESS INVESTMENT GROUP, LLC | New Position | 416,998 | May 14, 2026 |
| BOOTHBAY FUND MANAGEMENT, LLC | Unchanged | 194,536 | May 15, 2026 |
| ADAR1 CAPITAL MANAGEMENT, LLC | Reduced | 154,098 | May 18, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | Increased | 77,103 | May 15, 2026 |
| PALUMBO WEALTH MANAGEMENT LLC | New Position | 61,175 | May 12, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 55,193 | May 15, 2026 |
| VANGUARD FIDUCIARY TRUST CO | New Position | 31,804 | May 8, 2026 |
| STATE STREET CORP | Unchanged | 25,802 | May 15, 2026 |
| JANE STREET GROUP, LLC | New Position | 21,241 | May 12, 2026 |
| TWO SIGMA INVESTMENTS, LP | Unchanged | 19,244 | May 15, 2026 |
| LYNX1 CAPITAL MANAGEMENT LP | New Position | 15,078 | May 4, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Jul 16, 2026